Interferon-gamma production by mononuclear cells in Bacille Calmette-Guérin-revaccinated healthy volunteers predicted long-term antimycobacterial responses in a randomized controlled trial  by Oliveira, Evelin S. et al.
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The  Bacille  Calmette-Guérin  (BCG)  vaccine  is  the  only  vaccine  currently  available  for  tuberculosis,  and  it
demonstrates  variable  efﬁcacy  against  the  disease.  The  assessment  of new  vaccine  strategies  is hindered
by  the  small  annual  probability  that  an  infected  individual  will  develop  tuberculosis,  and  the  lack of
simple and  reliable  surrogate  markers  of  protection.  The  frequency  of  cytokine-producing  T  cells as  welleywords:
uberculosis vaccines
orrelates of protection
accine evaluation
as  the  production  of  IFN-  have  been  disputed  as surrogate  markers  of  protection.  We  evaluated  the
evolution  of  these  immune  parameters  in  a population  from  a high  burden  city  where  BCG  revaccination
has been  shown  to  result  in  mild  protection.  We  found  that  individuals  whose  in vitro  IFN-  responses
to mycobacterial  antigens  had  increased  by  more  than  3.3-fold  were  more  likely  to  maintain  higher
responses  after  1  year  and  to  show  increased  expansion  of IFN--producing  T  lymphocytes  than  those
se  of  uman populations with  lower  or  null  increa
. Introduction
Tuberculosis (TB) remains a major public health problem world-
ide, despite over 80% worldwide coverage achieved by the Bacille
almette-Guérin (BCG) vaccine. BCG efﬁcacy is highly variable
mong populations and is often low against pulmonary TB, which
imits its effectiveness at reducing TB transmission. Biomarkers are
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uman immunodeﬁciency virus; IFN-, interferon-gamma; IL, interleukin; Mtb, M.
uberculosis H37Rv culture lysate; PBMC, peripheral blood mononuclear cells; PHA,
hytohemagglutinin; PPD, protein puriﬁed derivative; roc, Receiver operating char-
cteristic; TB, tuberculosis; TST, tuberculin skin test; TNF, tumor necrosis factor.
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urgently needed to evaluate new vaccine strategies [1]. In spite
of being widely assessed the IFN- production to mycobacterial
antigen has been questioned as a valid biomarker [2].
In the BCG-protected population of the United Kingdom [3]
IFN- production to Mycobacterium tuberculosis protein puriﬁed
derivative (PPD) in whole blood cultures increased up to 11-fold [4]
1 year after BCG vaccination, while in Malawi where the vaccine has
no efﬁcacy BCG vaccination demonstrated up to 2-fold increase in
the levels of this cytokine [5]. Similar high IFN- responses among
children from the UK were also associated with the expansion of
IFN--producing T cells [6]. In the animal model, the total IFN-
response has demonstrated better association with the rate of pro-
tection than the response of antigen-speciﬁc CD4+ or CD8+ T cells
[7].
In Salvador, Bahia, Brazil BCG revaccination at school age
demonstrated moderate additional protection against TB, relative
to the priming vaccination [8]. Additionally, the IFN- response
to mycobacterial antigens was  increased at 2 months after BCG
revaccination only in a subset of the revaccinated children [9].
Therefore, we evaluated whether the fold increase in the in vitro
IFN- production to whole mycobacterial antigen post-BCG revac-
cination could be associated with the frequency of IFN-+/CD4+and CD8+ T cells as well as predict the response to the same stim-
ulus at 1 year post-revaccination for potential use as a parameter
to guide the selection of newly proposed immunization strategies
against TB.
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Fig. 1. A, IFN- production in whole blood cultures of volunteers randomly assigned to control (29) and BCG-revaccinated (46) groups. The numbers of individuals present
at  follow-up evaluations were: at T = 2, 28 revaccinated and 14 control subjects; at T = 12, 16 revaccinated and 14 controls (Supplementary Fig. 2). B and C, roc curves for
the  prediction of IFN- production at 12 months post-revaccination: B, model representing the prediction of IFN- responses above the median value obtained for the
r e the 
i
2
2
c
i
S
v
g
I
d
(
n
a
2
b
P
h
E
p
tevaccinated group; C, model representing the prediction of IFN- responses abov
ndividuals.
. Materials and methods
.1. Recruitment and study design
This was a prospective randomized controlled trial of BCG revac-
ination among tuberculin skin test (TST) negative and human
mmunodeﬁciency virus (HIV) negative university students from
alvador, Bahia, Brazil aged 18 years or older that had been
accinated with BCG in early childhood and presented distin-
uishable prime vaccination scars, identiﬁed in a TST survey [10].
nformed consent was obtained from all participants. Subjects
onated blood at baseline (T0), 2 months (T2) and 12 months
T12) after the ﬁrst intervention (Supplementary Fig. 1). Revacci-
ation was performed intradermally using a 26G × 1/2′′ needle
nd 1 ml  syringe in the deltoid region of the right arm at least
 cm apart from the previous BCG scar with one dose of 0.1 ml  M.
ovis BCG Moreau-RJ vaccine suspension (Fundacao Ataulpho de
aiva, reg. MS  101660001/007-6, Lot nr. 02P). Hemogram and
ematocrit values were measured using a hemocytometer (Coulter
lectronics, Hialeah, FL, USA). Serology against HIV-1 and HIV-2 was
erformed using a rapid test (DetermineTM HIV-1/2, Abbott Labora-
ories, Tokyo, Japan). A follow up clinical evaluation was performedmean value plus twice the standard deviation observed in the cultures of control
by one clinician and one dermatologist. The Ethical Committee
of the Centro de Pesquisas Gonc¸ alo Moniz approved this study
(CEP-CPqGM/FIOCRUZ, 19/2002) that complied with the ethical
principles contained in the Helsinki Declaration and the Brazilian
National Health Council Resolution 196/96 Guidelines.
2.2. Cultures
Whole blood cultures were performed as described in [9] from
vacuum-collected blood, with or without 10 g/ml of M.  tubercu-
losis H37Rv culture lysate (Mtb, Colorado State University, USA).
Plates were incubated at 37 ◦C with 5% CO2 and 98% humidity for
72 h and the culture supernatants were then recovered and stored
at −20 ◦C until analysis.
Peripheral blood mononuclear cells (PBMCs) were obtained
from the T0 and T2 samples using a Ficoll-Histopaque gradient
(Sigma–Aldrich, MO,  USA). Cells (2 × 105/well) were plated with no
stimuli or with phytohemagglutinin 5 g/ml (PHA; Sigma–Aldrich,
MO,  USA), 10 g/ml Mtb, or live M. bovis BCG Moreau-RJ strain
at 10 mycobacteria per monocyte (10:1 MOI). Live monocytes
were estimated from percent propidium iodide negative (1 g/ml,
3780 E.S. Oliveira et al. / Vaccine 31 (2013) 3778– 3782
F ducing
S vacci
T
S
s
B
m
m
t
b
D
w
w
a
e
S
2
c
W
c
u
t
c
iig. 2. Expansion of cytokine-producing CD4+ (A, C) and cytokine/granzyme A-pro
amples with less than 80% viable cells were discarded. The cultures from sixteen re
 = 0 and T = 2 were analyzed.
igma-Aldrich, MO,  USA) CD14 positive (Becton-Dickinson Bio-
ciences, San Jose, CA) of total PBMC counts.
The bacterial inocula were prepared as described [11]. Live
CG-stimulated cultures were incubated for 2 h in antibiotic-free
edium, washed and suspended in medium with antibiotics and
aintained for 6 or 48 h. The cytokines were measured in cul-
ure supernatants (Supplementary Table 2) using multiplexed
ead-based immunoassays (BD Cytometric Bead ArrayTM, Becton-
ickinson Biosciences, San Jose, CA). The T0 and T2 supernatants
ere evaluated simultaneously, whereas the T12 supernatants
ere assessed 1 year later. IL-17 was not assessed at T12. Cytokine
nd granzime A-producing T cells were quantitated by ﬂow cytom-
try using ﬂuorescent antibodies (Becton-Dickinson Biosciences,
an Jose, CA) as described [12].
.3. Statistical analyses
Volunteers were randomly assigned to the revaccinated or
ontrol groups using Microsoft Excel (Microsoft Co., Redmond,
A). Frequencies were compared using Fisher’s exact test or the
hi-squared test. The cytokine levels and ratios were compared
sing the Mann-Whitney U test or the Wilcoxon signed rank
est. All statistical tests were two tailed, and the differences were
onsidered signiﬁcant at P ≤ 0.05. Databanks were mounted
n EpiData Entry (EpiData Association, Denmark), and the data CD8+ (B, D) T cells in PBMC cultures stimulated with Mtb  (A, B) or live BCG (C, D).
nated (7 low ratio and 9 high ratio) and 9 control individuals with PBMC from both
were processed and analyzed using EpiData Analysis and Prism
(GraphPad Inc., San Diego, CA).
3. Results and discussion
3.1. Modulation of cytokine responses to Mtb upon revaccination
with BCG
Only revaccinated individuals demonstrated increased IFN-
and IL-10 production (Fig. 1A and Supplementary Table 2) in
Mtb-stimulated cultures at T2 compared to T0, and only IFN- lev-
els differed between the revaccinated and control subjects at T2
(P = 0.0362). The TNF levels were increased in both the control and
revaccinated subjects (Supplementary Table 2), which may  reﬂect
a nonspeciﬁc response to the TST performed prior to volunteers’
enrollment. IFN- production at T12 was also higher for revac-
cinated individuals compared to the T0 levels (Fig. 1A), although
these levels were not different from those observed in control vol-
unteer cultures (P = 0.0845). The other evaluated cytokines were
similar between the evaluation periods and between the control
and revaccinated groups (Supplementary Table 2).
3.2. Prediction of the IFN- response at 12 months post-BCG
revaccination
In Salvador, we  previously found that the IFN- responses in
Mtb-stimulated cultures from BCG-revaccinated adolescents were
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[E.S. Oliveira et al. / Va
ncreased up to 8-fold [9]. To determine whether the T2/T0 IFN-
atio in early whole blood cultures stimulated with Mtb  could
redict the IFN- response at 12 months post-BCG revaccination
e analyzed two endpoints: (i) IFN- production above the median
evel at T12 (Fig. 1B) and (ii) IFN- production above the mean
alue plus twice the standard deviation found in cultures of control
ndividuals at T12 (Fig. 1C). There was a signiﬁcant association
ith both endpoints, with high sensitivity and speciﬁcity for
he cut-off value corresponding to a ratio of 3.262. This was not
bserved when considering the absolute values of IFN- produc-
ion obtained post-BCG revaccination, which is in agreement with
he current view that the magnitude of the IFN- response is
nlikely to reﬂect vaccine efﬁcacy [2]. These data further suggest
hat there is a dichotomy in the response of the individuals to
CG revaccination, by which only part of the revaccinated subjects
how the development of a long lasting Th1 response. It must be
tressed that the number of individuals tested and the period of
ollow-up were insufﬁcient to investigate any direct association
etween the ratio of IFN- production and protection against the
evelopment of TB disease.
.3. In vitro expansion of T cell subsets from volunteers stratiﬁed
ccording to the IFN- ratio
We  used the ratio of 3.262 that was found to predict the long
erm IFN- response as a cut-off to assign the volunteers to “low-
atio” or “high-ratio” groups (Supplementary Fig. 2). We  compared
he expansion of cytokine- or granzyme A-producing T cells in
BMC cultures at T0 and T2 between the control, high-ratio and
ow-ratio individuals (Fig. 2). T cell expansion (IFN-+, TNF+ or
ranzyme A+ or IFN-/TNF+ CD4+ or CD8+ lymphocytes) follow-
ng Mtb  or live BCG stimulation relative to unstimulated cultures
as not different between the control, low-ratio, and high-ratio
ndividuals at T0 or T2. However, there was greater expansion
f CD4+IFN-+ cells upon stimulation with live BCG at T2 com-
ared to T0 among high-ratio volunteers (Fig. 2C) that was not
bserved among the controls or low-ratio individuals. Similarly,
reater CD8+ lymphocytes expansion (both single-positive and
FN-+/TNF+) was observed at T2 only in the high-ratio group
Fig. 2B and D). No differences in CD8+ granzyme A+ cells expan-
ion were observed following Mtb  or live BCG stimulation between
re- and post-BCG revaccination cultures. These ﬁndings are in
greement with those of Kagina et al. [13], who failed to demon-
trate any difference in BCG-induced T cell frequencies when
omparing children who developed TB with vaccine-protected chil-
ren.
The possibility that the ratio of the IFN- response within a
hort time pre- and post-vaccination may  reﬂect vaccine efﬁ-
acy may  signal novel approaches to improve the analysis of
ngoing vaccine trials. IFN- release assays are relatively inex-
ensive, highly reproducible, and easily applicable to large-scale
eld studies and continue to be developed and applied for the
iagnosis of TB and clinical outcome prediction [14]. The devel-
pment of similar tests to validate vaccine candidates would
e relatively easy and could have a signiﬁcant impact on accel-
rating vaccine research and development toward obtaining a
etter TB vaccine. Further epidemiologic studies are needed to
stablish a possible direct link between the IFN- response and
rotection against TB development in diverse human popula-
ions.
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Supplementary data associated with this article can be
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